ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

LEO Pharma, Almirall and Abbott side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

LEO Pharma×Almirall×Abbott×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

LEO PharmaAlmirallAbbott
studies on the registry254741,345
open to participants now5952
phase 3 studies under way330
reach primary completion within a year3624
programswith a study of their own in two years15none read

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseLEO PharmaAlmirallAbbott
Phase 100%

Almirall: 1 of its 5 programs at phase 1

  1. LAD106phase 1
20%
–
Phase 200%

Almirall: 3 of its 5 programs at phase 2

  1. LAD191phase 2
  2. LAD603phase 2
  3. LAD328phase 2
60%
–
Phase 3

LEO Pharma: 1 of its 1 programs at phase 3

  1. delgocitinibphase 3
100%

Almirall: 1 of its 5 programs at phase 3

  1. lebrikizumabphase 3
20%
–
Approved, new studies00%00%–

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
LEO Pharma1 readouts · 0 phase 3·······

LEO Pharma, Jun ’27: 1 program whose next study reaches primary completion

  1. delgocitinibphase 3 · Jun 4 · NCT07013201
····
Almirall5 readouts · 1 phase 3···

Almirall, Feb ’27: 1 program whose next study reaches primary completion

  1. LAD328phase 2 · Feb 0 · NCT07547813
·

Almirall, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. lebrikizumabphase 3 · Apr 25 · NCT06526182

Almirall, May ’27: 2 programs whose next study reaches primary completion

  1. LAD191phase 2 · May 25 · NCT07151937
  2. LAD106phase 1 · May 31 · NCT07471932

Almirall, Jun ’27: 1 program whose next study reaches primary completion

  1. LAD603phase 2 · Jun 23 · NCT07311564
····
Abbott0 readouts · 0 phase 3············
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

LEO Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Almirall

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Abbott

No programs read for this company.

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionLEO PharmaAlmirallAbbott
Alopecia Areata2 of 3 · compare here

LEO Pharma in Alopecia Areata: 1 program

  1. delgocitinibphase 3

Their studies: LEO Pharma’s studies of Alopecia Areata in search

Almirall in Alopecia Areata: 1 program

  1. LAD603phase 2

Their studies: Almirall’s studies of Alopecia Areata in search

–
Dermatitis, Atopic2 of 3 · compare here

LEO Pharma in Dermatitis, Atopic: 1 program

  1. delgocitinibphase 3

Their studies: LEO Pharma’s studies of Dermatitis, Atopic in search

Almirall in Dermatitis, Atopic: 1 program

  1. lebrikizumabphase 3

Their studies: Almirall’s studies of Dermatitis, Atopic in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: LEO Pharma 1 of 1 · Almirall 1 of 5 · Abbott 0 of 0 programs (2 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.